Eribulin

Generic Name: Eribulin

Brand Names: Halaven, Eribulin Baxter, Mevlyq

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₉NO_₁₁

CAS Number: 253128-41-5

Unique Ingredient Identifier: LR24G6354G

Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication: For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions: Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma

Clinical Trials

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2

Conditions: HER2-negative Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Anlotinib hydrochloride

First Posted Date: 2020-11-12

Last Posted Date: 2021-05-21

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 40

Registration Number: NCT04624711

Locations: 🇨🇳
Jiangsu Provincial Hospital, Nanjing, Jiangsu, China

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3

Recruiting

Conditions: Metastatic Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Bladder Urothelial Carcinoma
Refractory Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Docetaxel
Drug: Eribulin Mesylate
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Biological: Sacituzumab Govitecan

First Posted Date: 2020-10-08

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 184

Registration Number: NCT04579224

Locations: 🇺🇸
Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 427 locations

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Eribulin Mesylate

First Posted Date: 2020-08-06

Last Posted Date: 2020-08-11

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 100

Registration Number: NCT04502680

Locations: 🇨🇳
Jiangsu Provincial Hospital, Nanjing, Jiangsu, China

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Carboplatin
Drug: Eribulin
Drug: Capecitabine
Drug: Gemcitabine

First Posted Date: 2020-07-09

Last Posted Date: 2024-07-26

Lead Sponsor: MedSIR

Target Recruit Count: 54

Registration Number: NCT04464174

Locations: 🇪🇸
Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇵🇹
Champalimaud Clinical Centre - Champalimaud Foundation, Lisboa, Portugal

and more 11 locations

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Eribulin Mesylate
Drug: Copanlisib Hydrochloride
Procedure: Magnetic Resonance Imaging

First Posted Date: 2020-04-15

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT04345913

Locations: 🇺🇸
Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, United States
🇺🇸
Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 40 locations

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib
Drug: Eribulin

First Posted Date: 2020-03-11

Last Posted Date: 2023-04-12

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 46

Registration Number: NCT04303741

Locations: 🇨🇳
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, Shanghai, China

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date: 2019-04-24

Last Posted Date: 2019-04-24

Lead Sponsor: Xijing Hospital

Target Recruit Count: 300

Registration Number: NCT03925233

Locations: 🇨🇳
JingSu, Xi'an, Shaanxi, China

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin
Drug: Sacituzumab Govitecan-hziy
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2019-04-03

Last Posted Date: 2024-10-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 543

Registration Number: NCT03901339

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Maryland Oncology Hematology, P.A., Rockville, Maryland, United States

and more 110 locations

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Liposarcoma
Undifferentiated Pleomorphic Sarcoma
Sarcoma
Leiomyosarcoma

Interventions: Drug: Eribulin
Drug: Pembrolizumab

First Posted Date: 2019-04-02

Last Posted Date: 2024-12-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT03899805

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Eribulin in Advanced Solitary Fibrous Tumor

Phase 2

Recruiting

Conditions: Solitary Fibrous Tumor

Interventions: Drug: Eribulin

First Posted Date: 2019-02-15

Last Posted Date: 2023-09-13

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 16

Registration Number: NCT03840772

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo, PA, Italy
🇮🇹
Policlinico Universitario Campus Biomedico, Roma, RM, Italy
🇮🇹
Fondazione IRCCS INT Milano, Milano, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy